Список литературы

1. Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018; 11(1). doi: 10.1186/S13045-017-0549-1

2. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12): e538 - e548. doi: 10.1016/S1470-2045(14)70442-5

3. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012; 122(10): 3456 - 3463. doi: 10.1172/JCI61188

4. M Hallek, P L Bergsagel, K C Anderson Multiple myeloma: increasing evidence for a multistep transformation process - Blood 1998 Jan 1; 91(1): 3 - 21.

5. Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol. 2015; 20(3): 413 - 422. doi: 10.1007/S10147-015-0837-0

6. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006; 64(1): 210 - 217. doi: 10.1016/J.IJROBP.2005.06.039

7. Liebross RH, Ha CS, Cox JD, et al. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999; 52(3): 245 - 249. doi: 10.1016/S0167-8140(99)00114-0

8. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.; 2017.

9. Hill QA, Rawstron AC, De Tute RM, et al. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014; 124(8): 1296 - 1299. doi: 10.1182/BLOOD-2014-04-566521

10. Paiva B, Chandia M, Vidriales MB, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014; 124(8): 1300 - 1303. doi: 10.1182/BLOOD-2014-04-567909

11. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009; 23(2): 215 - 224. doi: 10.1038/LEU.2008.307

12. Grammatico S, Scalzulli E, Petrucci MT. Solitary Plasmacytoma. Mediterr J Hematol Infect Dis. 2017; 9(1). doi: 10.4084/MJHID.2017.052

13. Guo SQ, Zhang L, Wang YF, et al. Prognostic factors associated with solitary plasmacytoma. Onco Targets Ther. 2013; 6: 1659 - 1666. doi: 10.2147/OTT.S53248

14. Менделеева Л.П., Вотякова О.М. Солитарная Плазмоцитома//Российские Клинические Рекомендации По Диагностике и Лечению Злокачественных Лимфопролиферативных Заболеваний; Под Ред. И.В. Поддубной, В.Г. Савченко.; 2018.

15. Chang WI, Koh HK, Yoon SS, et al. The predictive value of serum myeloma protein in solitary plasmacytoma. Radiat Oncol J. 2020; 38(2): 129 - 137. doi: 10.3857/ROJ.2019.00570

16. Менделеева Л.П., Вотякова О.М. Множественная Миелома//Российские Клинические Рекомендации По Диагностике и Лечению Злокачественных Лимфопролиферативных Заболеваний; Под Ред. И.В. Поддубной, В.Г. Савченко. Москва; 2018.

17. Mendenhall WM, Mendenhall CM, Mendenhall NP. Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol. 2003; 24(6): 395 - 399. doi: 10.1016/S0196-0709(03)00092-9

18. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001; 50(1): 113 - 120. doi: 10.1016/S0360-3016(00)01572-8

19. Tsang RW, Campbell BA, Goda JS, et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018; 101(4): 794 - 808. doi: 10.1016/J.IJROBP.2018.05.009

20. Knobel D, Zhouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006; 6. doi: 10.1186/1471-2407-6-118

21. Holland J, Trenkner D A, Wasserman T H et al. Plasmacytoma. Treatment results and conversion to myeloma - PubMed. Cancer. 1992; 69(6): 1513 - 1517. https://pubmed.ncbi.nlm.nih.gov/1540888/. Accessed January 27, 2022.

22. Kayane Mheidly, Thierry Lamy, Martine Escoffre, et al. Adjuvant chemotherapy in the treatment of solitary bone plasmacytoma. 2016.

23. Mignot F, Schernberg A, Ars ne-Henry A, et al. Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes. Int J Radiat Oncol Biol Phys. 2020; 106(3): 589 - 596. doi: 10.1016/J.IJROBP.2019.10.043

24. Wilder RB, Ha CS, Cox JD, et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002; 94(5): 1532 - 1537. http://www.ncbi.nlm.nih.gov/pubmed/11920511. Accessed May 18, 2017.

25. M M Oken, R H Creech, D C Tormey, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649 - 655. doi: 10.1097/00000421-198212000-00014

26. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am.J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.